Vantage logo

Can Gilead make remdesivir pay?

Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.

Vantage logo

Rubius confirms the worst

The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.

Vantage logo

Why Novo Nordisk should buy Uniqure

Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.

Vantage logo

Reality bites for Macrogenics 

Hopes are fading for margetuximab in breast cancer, which looks unlikely to show an overall survival benefit in the Sophia study.